Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Maricla Galetti

Third Generation EGFR Inhibitor Osimertinib Combined With Pemetrexed or Cisplatin Exerts Long-Lasting Anti-Tumor Effect in EGFR-mutated Pre-Clinical Models of NSCLC

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2019English

Gefitinib Inhibits Invasive Phenotype and Epithelial-Mesenchymal Transition in Drug-Resistant NSCLC Cells With MET Amplification

PLoS ONE
Multidisciplinary
2013English

Related publications

Trastuzumab Emtansine Delays and Overcomes Resistance to the Third-Generation EGFR-TKI Osimertinib in NSCLC EGFR Mutated Cell Lines

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2017English

Switching From First or Second Generation EGFR-TKI to Osimertinib in EGFR Mutation-Positive NSCLC

Lung Cancer Management
2020English

Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models With EGFR Activating Mutations, T790M Mutation and AXL Overexpression

Molecular Cancer Therapeutics
Cancer ResearchOncology
2019English

P1.01-81 Phase 3 Study of Pemetrexed-Platinum With or Without Pembrolizumab for TKI-Resistant/EGFR-Mutated Advanced NSCLC: KEYNOTE-789

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Osimertinib With Ramucirumab in EGFR Mutated, T790m-Positive Patients Who Had Progressed EGFR-TKIs: Phase Ib Study

Clinical Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2018English

Third Generation EGFR TKI Landscape for Metastatic EGFR Mutant Non-Small Cell Lung Cancer (NSCLC)

Expert Review of Anticancer Therapy
OncologyPharmacology
2019English

Overcoming T790M Mutant Small Cell Lung Cancer With the Third-Generation EGFR-TKI Osimertinib

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2018English

Osimertinib Plus Durvalumab Versus Osimertinib Monotherapy in EGFR T790m-Positive NSCLC Following Previous EGFR-TKI Therapy: CAURAL Brief Report

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy